8-K: Vaxart Receives Nasdaq Non-Compliance Notice Due to Low Share Price

Vaxart has received a notice from Nasdaq for not meeting the minimum bid price requirement of $1.00 per share, placing its listing status at risk.

Summary

• Vaxart received a notice from Nasdaq on July 2, 2024, stating that the company is not in compliance with the minimum bid price requirement of $1.00 per share.
• This non-compliance is due to the company's stock price closing below $1.00 for 30 consecutive business days between May 17, 2024, and July 1, 2024.
• Vaxart has been granted a 180-day period, until December 30, 2024, to regain compliance by having its stock price close at or above $1.00 for at least ten consecutive business days.
• If the company fails to regain compliance within the initial 180-day period, it may be eligible for an additional 180-day compliance period if it meets other listing requirements and notifies Nasdaq of its intention to cure the deficiency, potentially through a reverse stock split.
• If Vaxart does not regain compliance, it may face delisting from The Nasdaq Capital Market, which could be appealed to a Hearings Panel.
• The company is actively monitoring its stock price and considering options to regain compliance, but there is no guarantee that it will be successful.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event (non-compliance notice) and potential delisting, which is concerning for investors. The company is taking steps to address the issue, but there is no guarantee of success.

Positives

• Vaxart has been given 180 days to regain compliance with the minimum bid price requirement.
• The company may be eligible for an additional 180-day compliance period if it meets certain conditions.
• Vaxart is actively monitoring its stock price and considering options to regain compliance.

Negatives

• Vaxart is currently not in compliance with Nasdaq's minimum bid price requirement.
• The company's stock price has been below $1.00 for 30 consecutive business days.
• There is no guarantee that Vaxart will be able to regain compliance with the listing requirements.
• Failure to regain compliance could result in delisting from The Nasdaq Capital Market.

Risks

• There is a risk that Vaxart will not be able to increase its stock price to $1.00 or above for ten consecutive business days within the given timeframe.
• The company may need to implement a reverse stock split to regain compliance, which could negatively impact shareholders.
• Delisting from The Nasdaq Capital Market could significantly reduce the company's visibility and access to capital.
• The company's ability to raise capital may be impacted by the non-compliance notice.

Future Outlook

Vaxart intends to actively monitor its stock price and is considering its options to regain compliance with the Bid Price Requirement, but there is no assurance that it will be successful.

Management Comments

• The company intends to actively monitor the closing bid price of its common stock and is considering its options to regain compliance with the Bid Price Requirement.

Industry Context

This announcement is not unique, as many small-cap biotech companies face challenges in maintaining their stock price above the minimum bid price required for Nasdaq listing. This is often due to the high-risk nature of drug development and the volatility of the biotech sector.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges with maintaining minimum bid prices on exchanges like Nasdaq.
• Companies like Cassava Sciences (SAVA) and Ocugen (OCGN) have also faced similar delisting risks due to low share prices.
• The 180-day compliance period is a standard procedure for Nasdaq-listed companies facing bid price deficiencies.
• Reverse stock splits are a common method used by companies to regain compliance, but they can be viewed negatively by investors.

Stakeholder Impact

• Shareholders face the risk of further stock price decline and potential delisting.
• Employees may experience uncertainty due to the company's financial challenges.
• The company's ability to raise capital may be impacted, potentially affecting future operations and research.

Next Steps

• Vaxart will monitor its stock price to try and regain compliance.
• The company will consider options to regain compliance, including a potential reverse stock split.
• Vaxart will need to achieve a closing bid price of at least $1.00 for ten consecutive business days before December 30, 2024, to avoid delisting.

Key Dates

Keywords

Nasdaq, delisting, minimum bid price, compliance, stock price, reverse stock split, VXRT